By Christopher Sims, MD, President & Co-Founder
The struggle for companies to successfully transition promising preclinical research to late-stage clinical trials has existed for decades. Roughly 85–90% of drug candidates either display toxic side effects or fail to show efficacy once they are tested in real-world conditions. Rectifying this issue would lead to a massive growth in efficiency for pharmaceutical companies, reducing costs and freeing resources to invest in other innovations. It is here that Altis Biosystems can enhance the robustness of preclinical research, improving the quality of predictive models so that researchers can have increased confidence in the viability of drug candidates as they progress into clinical trials.